Table 2. irAEs and cytokines.
| irAEs/cytokines | No COPD (n1=19) | Mild group (n2=24) | Moderate group (n3=31) | Severe group (n4=25) | P value |
|---|---|---|---|---|---|
| irAEs | 21.1%i | 8.3% | 32.3%ii | 56.0% | 0.003 |
| Fatigue | 15.8% | 8.33% | 22.6% | 36.0% | |
| Pruritus | 5.26% | 4.17% | 12.9% | 16.0% | |
| Immune-related enteritis | 5.26% | 4.17% | 0 | 8.00% | |
| Immune-related pneumonia | 5.26% | 0 | 3.23% | 28.0% | |
| Immune-related hepatitis | 0 | 0 | 0 | 8.00% | |
| Cytokines | |||||
| IL-6 (pg/mL) | 7.95±9.71 | 11.65±14.81 | 14.38±12.72iii | 37.74±40.45 | 0.000 |
| IL-8 (pg/mL) | 14.89±11.28 | 27.37±32.53 | 19.30±17.72iv | 61.03±69.19 | 0.030 |
| IL-10 (pg/mL) | 2.52±2.69 | 3.37±2.00 | 3.07±2.29v | 4.67±2.42 | 0.024 |
| KL-6 (U/mL) | 1,209±1,266 | 472±263 | 537±304 | 644±521 | 0.029 |
The data are expressed as % or mean ± SD. i, no COPD group vs. severe COPD group (P=0.024); ii, mild to moderate COPD group vs. severe COPD group (P=0.003); iii, mild to moderate COPD group vs. severe COPD group (P=0.000); iv, mild to moderate COPD group vs. severe COPD group (P=0.026); v, mild to moderate COPD group vs. severe COPD group (P=0.010). irAEs, immune-related adverse events; COPD, chronic obstructive pulmonary disease; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; KL-6, Krebs Von den Lungen-6; SD, standard deviation.